IDH1 and cholangiocarcinoma: The FDA has approved ivosidenib for treating adult patients with unresectable or metastatic IDH1-mutated CCA as detected by an FDA-approved test, specifically in cases where the disease has progressed after one to two prior lines of systemic therapy for advanced disease.